COMPANY:

Roche

"FoundationOne CDx as a companion diagnostic for this therapy marks the company’s first approval leveraging its real-world data-powered CDx offering, a service that supports drug and diagnostic label expansion by supplementing clinical trials with expertly curated real-world evidence and integrated regulatory support."

"Intensive chemotherapy (IC) was given in 42%, lower intensity regimens (LIR; hypomethylating agent +/-venetoclax) in 47%, and 146 (29%) received hematopoietic stem cell transplantation (HSCT)... Unsupervised clustering identified six clinically distinct AML subgroups with OS differences independent of ELN 2022 risk classification. Cluster assignment was driven not only by dominant mutations but also by VAF and coM patterns, highlighting molecular heterogeneity beyond single-gene models."

"Rituximab (7.7%) and hydroxychloroquine (4.8%) were the most common prior immunotherapies.Baseline disease characteristics at NGS were comparable across exposure groups. Prior immune and/or chemo-radiotherapy exposures in ZRSR2-mutated myeloid neoplasms are associated with altered clinical phenotypes characterized by lower blast burden and distinct diagnostic classification without major molecular differences. Despite this less proliferative phenotype, exposed patients demonstrated numerically worse survival, with significant heterogeneity by prior neoplasm subtype, suggesting that exposure history may modify disease biology beyond baseline disease burden."

"Roche...announced today that it has entered into a definitive merger agreement to acquire PathAI, a US-based company in digital pathology and AI-powered technology for pathology laboratories and the biopharma industry. This acquisition builds on the successful partnership between Roche and PathAI, established in 2021 and scaled up in 2024 to include the development of AI-enabled companion diagnostic algorithms. Subject to the closing of the transaction, which is expected in the second half of the year, the acquired entity will become part of the Diagnostics division."

"These infections can be difficult to detect due to nonspecific symptoms and have high morbidity and mortality.Case Report The patient is a 41-year-old male with a history of non-ischemic cardiomyopathy with LVAD placement (2015) complicated by chronic driveline infection status post 3 HTs: first in 2017 with antibody mediated rejection requiring ECMO/ATG/IVIG/PLEX/bortezomib; then in 2020 with early vasculopathy treated with multivessel PCI and tocilizumab; third HT in 6/2025. Findings were consistent with a ruptured mycotic aneurysm.Summary Antifungal prophylaxis in HT recipients is only administered in specific case scenarios and not universally. This case suggests that re-do HT recipients, given their cumulative immunosuppression exposure, may also benefit from fungal prophylaxis."

"She was listed for OHT following desensitization with IVIG, PLEX, and tocilizumab...The patient is over 1-year post OHT and doing well without any episodes of rejection.Summary Using PLEX to replace 1.5x plasma volumes with FFP is an effective method to rapidly replete F11 levels in a volume neutral manner allowing for OHT of our sensitized patient. This case serves as a model for rapid optimization of patients with HC for urgent surgery in a volume neutral manner."

"He received ATG induction and cyclosporine (neurologic side effects with tacrolimus), mycophenolate mofetil (MMF), and prednisone taper for maintenance...He was subsequently transitioned from cyclosporine to everolimus...His tacrolimus was transitioned to sirolimus...His MMF was discontinued, and he is currently undergoing R-CHOP.Summary Recipients of HLT may face a higher risk of developing PTLD compared to those who receive single-organs. Larger, more comprehensive studies are necessary to confirm this observed trend and modifiable risk factors. If confirmed, HLT pts could potentially benefit from reduced immunosuppression regimen, leveraging immunologic tolerance associated with liver transplantation."

P1/2 | "Early MR (by C2D1) was achieved in 35% of patients and strongly associated with improved rPFS and OS while PSA50 responses by C2D1 were not observed in any patients. The rPFS benefit of adding olaparib to radium-223 appeared more evident in those who achieved a MR. Early on treatment ctDNA dynamics in bone-dominant mCRPC may be a valuable tool for treatment decisions with radium-223 therapy."

"Descriptive statistics were used to describe safety endpoints (cytokine release syndrome [CRS], immune effector cell– associated neurotoxicity syndrome [ICANS], cytopenia) and HCRU (tocilizumab/steroid use, hospitalization). In this retrospective RW analysis, liso-cel demonstrated similar effectiveness and a more favorable safety and HCRU profile versus axi-cel as a 2L therapy for R/R LBCL. Despite limited follow-up, these RW findings suggest liso-cel could deliver safety advantages without compromising efficacy in a broad population of patients with 2L LBCL. 1 ."